Friday, July 10, 2026
🇺🇸 FDA

pharma · Generalized Myasthenia Gravis · Chronic inflammatory demyelinating polyneuropathy (CIDP)

Argenx

argenx

Argenx clinical programs — 32 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
33 Arch Street, Suite 3201, Boston, MA 02110, US HQ
2008 Founded
2,179 Employees
NMPA registrant Type
Company details
Status
Public
HQ
33 Arch Street, Suite 3201, Boston, MA 02110, US
Founded
2008
Employees
2,179
Programs
32
Drugs
16
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

Argenx projects

32 ClinicalTrials.gov programs sponsored by Argenx.

Argenx has 32 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

32 programs

Clinical programs

  1. ARGX-113

    argenx

    Primary immune thrombocytopenia

    phase 3 small molecule active

    1 trial

  2. ARGX-113

    argenx

    Primary Immune Thrombocytopenia

    phase 3 small molecule active

    1 trial

  3. ARGX-113-2007

    argenx

    Active Idiopathic Inflammatory Myopathy (IIM)

    phase 3 small molecule active

    1 trial

  4. ARGX-113-2008

    argenx

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  5. ARGX-113-2009

    argenx

    Bullous Pemphigoid (BP)

    phase 3 small molecule active

    1 trial

  6. ARGX-113-2306

    argenx

    Primary Sjögren’s Disease

    phase 3 small molecule active

    1 trial

  7. ARGX-113-2308

    argenx

    Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  8. ARGX-113-2309

    argenx

    Thyroid Eye Disease (TED)

    phase 3 small molecule active

    1 trial

  9. ARGX-113-2315

    argenx

    Ocular Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  10. ARGX-113-2402

    argenx

    Primary Immune thrombocytopenia (ITP)

    phase 3 small molecule active

    1 trial

  11. ARGX-117-2302

    argenx

    Multifocal Motor Neuropathy

    phase 3 small molecule active

    1 trial

  12. ARGX-117-2401

    argenx

    Chronic inflammatory demyelinating polyneuropathy (CIDP)

    phase 3 small molecule active

    1 trial

  13. ARGX-117-2402

    argenx

    Chronic inflammatory demyelinating polyneuropathy (CIDP)

    phase 3 small molecule active

    1 trial

  14. EFG PH20 SC

    argenx

    Active Idiopathic Inflammatory Myopathy

    phase 3 mab active

    1 trial

  15. Efgartigimod PH20 SC

    argenx

    Primary Sjogrens Disease

    phase 3 mab active

    1 trial

  16. Efgartigimod, Placebo for efgartigimod

    argenx

    Thyroid Eye Disease (TED)

    phase 3 small molecule active

    1 trial

  17. PBO PH20 SC, ARGX-113

    argenx

    Bullous Pemphigoid

    phase 3 small molecule active

    1 trial

  18. Placebo for efgartigimod, ARGX-113

    argenx

    Chronic Idiopathic thrombocytopenic purpura

    phase 3 small molecule active

    1 trial

  19. Vyvgart 1 000 mg solution for injection

    argenx

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  20. Vyvgart 20 mg/mL concentrate for solution for infusion

    argenx

    Generalized Myasthenia Gravis (gMG)

    phase 3 small molecule active

    1 trial

  21. Vyvgart 20 mg/mL concentrate for solution for infusion

    argenx

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  22. efgartigimod PH20 SC

    argenx

    Bullous Pemphigoid

    phase 3 mab completed

    1 trial

  23. ARGX-113-2302

    argenx

    Antibody-Mediated Rejection

    phase 2 small molecule active

    1 trial

  24. ARGX-113-2317

    argenx

    Systemic Sclerosis

    phase 2 small molecule active

    1 trial

  25. ARGX-117, ARGX-113

    argenx

    AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis, MG, gMG

    phase 2 small molecule active

    1 trial

  26. ARGX-117-2003

    argenx

    Multifocal Motor Neuropathy

    phase 2 small molecule active

    1 trial

  27. ARGX-117-2301

    argenx

    Myositis, Dermatomyositis

    phase 2 small molecule active

    1 trial

  28. ARGX-119-2302

    argenx

    congenital neuromuscular disorders

    phase 2 other active

    1 trial

  29. ARGX-119-2303

    argenx

    Amyotrophic Lateral Sclerosis (ALS)

    phase 2 small molecule active

    1 trial

  30. Efgartigimod, ARGX-113

    argenx

    Chronic Inflammatory Demyelinating Polyneuropathy

    phase 2 small molecule active

    1 trial

  31. A study to assess the safety of ARGX-121 in Healthy Adult Participants

    argenx

    Healthy volunteers

    phase 1 other active

    1 trial

  32. ARGX-113-2405

    argenx

    not applicable

    phase 1 other active

    1 trial

Frequently asked questions

How many clinical projects does Argenx have?

32 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.